Skip to main content
    P

    Prothena Corporation plc (PRTA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $7.97
    -0.19 (-2.33%)

    Market Cap: $419.01M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Prothena Corporation plc (PRTA) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Prothena Corporation are PepGen (PEPG), Phathom Pharmaceuticals (PHAT) and Prelude Therapeutics (PRLD). By market cap, Prothena Corporation ranks 5th of the 13 companies on this page; Geron (GERN) is the largest at $622.98M.

    Peer Comparison

    PRTA's revenue growth of -74.3% is below the peer median of 11.8%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Prothena Corporation (PRTA)$419.01MN/A7.8x-45.4%N/A-74.3%0.00%
    PepGen Ltd (PEPG)$410.98MN/AN/A0.0%N/A0.0%0.00%
    Phathom Pharmaceuticals Inc (PHAT)$492.63MN/A1.8x-30.2%11.4%71.1%0.00%
    Prelude Therapeutics Inc (PRLD)$275.32MN/A16.3x-269.7%N/A41.0%0.00%
    Rocket Pharmaceuticals Inc (RCKT)$256.82MN/AN/A0.0%-2.3%0.0%0.00%
    Gyre Therapeutics Inc. (GYRE)$471.74MN/A3.8x-22.7%N/A0.7%0.00%
    Enanta Pharmaceuticals Inc (ENTA)$320.09MN/A4.8x-96.9%N/A-21.6%0.00%
    Protalix Biotherapeutics Inc (PLX)$257.17M12.1x2.9x24.3%N/A22.8%0.00%
    Contineum Therapeutics, Inc. Class A Common Stock (CTNM)$387.16MN/AN/A0.0%N/A0.0%0.00%
    Neurogene Inc (NGNE)$495.37MN/AN/A0.0%-28.5%0.0%0.00%
    ProQR Therapeutics BV (PRQR)$199.28MN/A6.1x-228.2%N/A120.4%0.00%
    Geron Corporation (GERN)$622.98MN/A2.9x-22.0%-7.4%27.4%0.00%
    Precision BioSciences Inc (DTIL)$288.76MN/A4.4x-85.6%-38.3%37272.0%0.00%
    Peer median$353.62M12.1x4.1x-22.4%-7.4%11.8%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Prothena Corporation, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    PepGen Ltd (PEPG)
    PepGen Inc., a clinical-stage biotechnology company, is focused on the development of oligonucleotide therapeutics for use in the treatment of serious...
    PEPG competitors
    Phathom Pharmaceuticals Inc (PHAT)
    Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases.
    PHAT competitors
    Prelude Therapeutics Inc (PRLD)
    Prelude Therapeutics Incorporated, a precision clinical-stage oncology company, focuses on the discovery and development of small molecule therapies optimized...
    PRLD competitors
    Rocket Pharmaceuticals Inc (RCKT)
    Rocket Pharmaceuticals, Inc., is a cross-platform biotechnology company focused on developing gene therapies for rare and devastating pediatric diseases.
    RCKT competitors
    Gyre Therapeutics Inc. (GYRE)
    Gyre Therapeutics Inc. is a pioneering biopharmaceutical company at the forefront of developing advanced therapies for rare and complex diseases.
    GYRE competitors
    Enanta Pharmaceuticals Inc (ENTA)
    Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases.
    ENTA competitors
    Protalix Biotherapeutics Inc (PLX)
    Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its...
    PLX competitors
    Contineum Therapeutics, Inc. Class A Common Stock (CTNM)
    Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies...
    CTNM competitors
    Neurogene Inc (NGNE)
    Neurogene Inc. is an innovative biotechnology company at the forefront of developing advanced gene therapies for rare neurological disorders...
    NGNE competitors
    ProQR Therapeutics BV (PRQR)
    ProQR Therapeutics NV, a biopharmaceutical company, is dedicated to the discovery and development of RNA-based therapies for the treatment of genetic disorders.
    PRQR competitors
    Geron Corporation (GERN)
    Geron Corporation, an advanced stage clinical biopharmaceutical company, focuses on the development and commercialization of therapies for myeloid hematologic...
    GERN competitors
    Precision BioSciences Inc (DTIL)
    Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States.
    DTIL competitors

    Frequently Asked Questions About PRTA

    Who are Prothena Corporation's main competitors?

    The companies most similar to Prothena Corporation include PepGen (PEPG), Phathom Pharmaceuticals (PHAT), Prelude Therapeutics (PRLD), Rocket Pharmaceuticals (RCKT) and Gyre Therapeutics (GYRE), listed from the closest match.

    Who is Prothena Corporation's biggest competitor?

    Geron (GERN) is the largest of the similar companies at $622.98M; PepGen (PEPG) is the closest match by business profile, size, sector and industry.

    How does PRTA stock compare with its competitors?

    PRTA's P/S is 7.8x against a peer median of 4.1x; its net margin is -45.4% against a peer median of -22.4%.

    Which of Prothena Corporation's competitors pays a higher dividend?

    Prothena Corporation pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Prothena Corporation bigger than its competitors?

    No. Prothena Corporation is 5th by market cap among the 13 companies on this page; the largest is Geron (GERN) at $622.98M.